ZNTL – Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc.ZNTL
$1.54Name : Zentalis Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $110,446,168.00
EPSttm : -3.14
Zentalis Pharmaceuticals, Inc.
$1.54
4.42%$0.065Float Short %
11.09
Margin Of Safety %
Put/Call OI Ratio
1.21
EPS Next Q Diff
0.16
EPS Last/This Y
0.12
EPS This/Next Y
0.16
Price
1.47
Target Price
6.28
Analyst Recom
2.11
Performance Q
-23.83
Relative Volume
1.25
Beta
1.61
Ticker: ZNTL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | ZNTL | 1.23 | 1.57 | 0.00 | 998 |
| 2025-05-08 | ZNTL | 1.26 | 1.57 | 10.00 | 999 |
| 2025-05-09 | ZNTL | 1.225 | 1.57 | 10.00 | 999 |
| 2025-05-12 | ZNTL | 1.285 | 1.57 | 10.00 | 999 |
| 2025-05-13 | ZNTL | 1.21 | 1.57 | 10.00 | 999 |
| 2025-05-14 | ZNTL | 1.185 | 1.60 | 6.25 | 1008 |
| 2025-05-15 | ZNTL | 1.25 | 1.70 | 32.48 | 1065 |
| 2025-05-16 | ZNTL | 1.255 | 1.70 | 7.49 | 1065 |
| 2025-05-19 | ZNTL | 1.24 | 1.38 | 0.00 | 999 |
| 2025-05-20 | ZNTL | 1.281 | 1.38 | 0.00 | 1000 |
| 2025-05-21 | ZNTL | 1.215 | 1.24 | 999.99 | 1046 |
| 2025-05-22 | ZNTL | 1.23 | 1.25 | 0.00 | 1047 |
| 2025-05-23 | ZNTL | 1.195 | 1.25 | 0.00 | 1046 |
| 2025-05-27 | ZNTL | 1.195 | 1.25 | 0.00 | 1046 |
| 2025-05-28 | ZNTL | 1.245 | 1.16 | 0.00 | 1083 |
| 2025-05-29 | ZNTL | 1.255 | 1.16 | 0.00 | 1083 |
| 2025-05-30 | ZNTL | 1.215 | 1.16 | 130.00 | 1083 |
| 2025-06-02 | ZNTL | 1.275 | 1.67 | 999.99 | 1345 |
| 2025-06-03 | ZNTL | 1.37 | 1.67 | 0.00 | 1347 |
| 2025-06-04 | ZNTL | 1.51 | 1.66 | 0.01 | 1351 |
| 2025-06-05 | ZNTL | 1.46 | 1.21 | 0.00 | 1544 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | ZNTL | 1.23 | -533.5 | - | -2.25 |
| 2025-05-08 | ZNTL | 1.26 | -533.5 | - | -2.25 |
| 2025-05-09 | ZNTL | 1.23 | -533.5 | - | -2.25 |
| 2025-05-12 | ZNTL | 1.29 | -533.5 | - | -2.25 |
| 2025-05-13 | ZNTL | 1.21 | -533.5 | - | -2.25 |
| 2025-05-14 | ZNTL | 1.18 | -533.5 | - | -2.25 |
| 2025-05-15 | ZNTL | 1.26 | -533.5 | - | -2.25 |
| 2025-05-16 | ZNTL | 1.26 | -533.5 | - | -2.25 |
| 2025-05-19 | ZNTL | 1.25 | 50.3 | - | -2.25 |
| 2025-05-20 | ZNTL | 1.28 | 58.0 | - | -2.25 |
| 2025-05-21 | ZNTL | 1.22 | 58.0 | - | -2.25 |
| 2025-05-22 | ZNTL | 1.24 | 58.0 | - | -2.25 |
| 2025-05-23 | ZNTL | 1.19 | 58.0 | - | -2.25 |
| 2025-05-27 | ZNTL | 1.20 | 58.6 | - | -2.21 |
| 2025-05-28 | ZNTL | 1.25 | 58.6 | - | -2.21 |
| 2025-05-29 | ZNTL | 1.25 | 58.6 | - | -2.21 |
| 2025-05-30 | ZNTL | 1.21 | 58.6 | - | -2.21 |
| 2025-06-02 | ZNTL | 1.28 | 58.6 | - | -2.21 |
| 2025-06-03 | ZNTL | 1.36 | 58.6 | - | -2.21 |
| 2025-06-04 | ZNTL | 1.50 | 58.6 | - | -2.21 |
| 2025-06-05 | ZNTL | 1.47 | 58.6 | - | -2.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | ZNTL | 0.62 | -7.47 | 9.73 |
| 2025-05-08 | ZNTL | 0.62 | -7.47 | 9.74 |
| 2025-05-09 | ZNTL | 0.62 | -7.47 | 9.74 |
| 2025-05-12 | ZNTL | 0.62 | -5.41 | 10.71 |
| 2025-05-13 | ZNTL | 0.63 | -5.41 | 10.71 |
| 2025-05-14 | ZNTL | 0.63 | -5.41 | 10.71 |
| 2025-05-15 | ZNTL | 0.63 | -5.41 | 10.71 |
| 2025-05-16 | ZNTL | 0.63 | -5.41 | 10.71 |
| 2025-05-19 | ZNTL | 0.63 | 9.00 | 10.47 |
| 2025-05-20 | ZNTL | 0.67 | 9.00 | 10.47 |
| 2025-05-21 | ZNTL | 0.67 | 9.00 | 10.47 |
| 2025-05-22 | ZNTL | 0.67 | 9.00 | 10.47 |
| 2025-05-23 | ZNTL | 0.67 | 9.00 | 10.47 |
| 2025-05-27 | ZNTL | 0.67 | -15.14 | 10.47 |
| 2025-05-28 | ZNTL | 0.67 | -15.14 | 11.09 |
| 2025-05-29 | ZNTL | 0.67 | -15.14 | 11.09 |
| 2025-05-30 | ZNTL | 0.67 | -15.14 | 11.09 |
| 2025-06-02 | ZNTL | 0.67 | -11.65 | 11.09 |
| 2025-06-03 | ZNTL | 0.67 | -11.65 | 11.09 |
| 2025-06-04 | ZNTL | 0.67 | -11.65 | 11.09 |
| 2025-06-05 | ZNTL | 0.67 | -11.65 | 11.09 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.67
Avg. EPS Est. Current Quarter
-0.51
Avg. EPS Est. Next Quarter
-0.51
Insider Transactions
0.67
Institutional Transactions
-11.65
Beta
1.61
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
17
Growth Score
23
Sentiment Score
37
Actual DrawDown %
98.3
Max Drawdown 5-Year %
-98.8
Target Price
6.28
P/E
Forward P/E
PEG
P/S
3.94
P/B
0.36
P/Free Cash Flow
EPS
-3.15
Average EPS Est. Cur. Y
-2.21
EPS Next Y. (Est.)
-2.05
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-834.49
Relative Volume
1.25
Return on Equity vs Sector %
-99.9
Return on Equity vs Industry %
-82.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
Zentalis Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 166
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, for the treatment of advanced solid tumors and hematological malignancies. It is in a Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; a Phase 2 clinical trial in Cyclin E1-driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; a Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; a Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, peritoneal, or fallopian tube cancer; a Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; a Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and a Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's product pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; and Dana-Farber. The company was incorporated in 2014 and is headquartered in New York, New York.
stock quote shares ZNTL – Zentalis Pharmaceuticals, Inc. Stock Price stock today
news today ZNTL – Zentalis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ZNTL – Zentalis Pharmaceuticals, Inc. yahoo finance google finance
stock history ZNTL – Zentalis Pharmaceuticals, Inc. invest stock market
stock prices ZNTL premarket after hours
ticker ZNTL fair value insiders trading